Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Italian car maker Fiat is opening an apartment building in Fort Lee, New Jersey.
Actress Sarah Michelle Gellar has teamed up with Fidelity to set kids up for success.
LinkedIn is rolling out generative AI tools for premium members.
Closing arguments began in the trial of FTX co-founder Sam Bankman Fried.
AMD posted higher third-quarter earnings, CVS reported better-than-expected results and Kraft raised its full-year forecast.
Collins Dictionary has named its word of the year: A.I.
The Federal Reserve Board will announce its decision on interest rates following the conclusion of its two-day meeting.
UPS is gearing up for a mass hiring event that could help a critical labor shortage affecting the U.S. across all industries. Jon Bowers, human resources director with UPS, joined Cheddar News to discuss the company's job fair known as 'Brown Friday,' which is slated to take place Nov. 3 and Nov. 4, ahead of the holiday season.
A Missouri jury found the National Association of Realtors and other brokerages liable for nearly $1.8 billion in damages on Tuesday. The jury found the parties conspired to keep commissions for home sales artificially high and the lawsuit looked at sales that took place between April of 2015 through June of 2022.
Stocks were little changed in the opening session on Wednesday ahead of the interest rate decision by the Federal Reserve later.
